1
|
Marden S, Campbell JM, Adams N, Coelho R, Foti C, Franca JR, Hostyn S, Huang Z, Ultramari M, Zelesky T, Baertschi SW. Mass Balance in Pharmaceutical Stress Testing: A Review of Principles and Practical Applications. AAPS J 2024; 26:96. [PMID: 39174806 DOI: 10.1208/s12248-024-00961-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2024] [Accepted: 07/24/2024] [Indexed: 08/24/2024] Open
Abstract
Stress testing (also known as forced degradation) of pharmaceutical drug substances and products is a critical part of the drug development process, providing insight into the degradation pathways of drug substances and drug products. This information is used to support the development of stability-indicating methods (SIMs) capable of detecting pharmaceutically relevant degradation products that might potentially be observed during manufacturing, long-term storage, distribution, and use. Assessing mass balance of stressed samples is a key aspect of developing SIMs and is a regulatory expectation. However, the approaches to measure, calculate, and interpret mass balance can vary among different pharmaceutical companies. Such disparities also pose difficulties for health authorities when reviewing mass balance assessments, which may result in the potential delay of drug application approvals. The authors have gathered input from 10 pharma companies to map out a practical review of science-based approaches and technical details to assess and interpret mass balance results. Key concepts of mass balance are introduced, various mass balance calculations are demonstrated, and recommendations on how to investigate poor mass balance results are presented using real-world case studies. Herein we provide a single source reference on the topic of mass balance in pharmaceutical forced degradation for small molecule drug substances and drug products in support of regulatory submissions with the goal of facilitating a shared understanding among pharmaceutical scientists and health authorities.
Collapse
Affiliation(s)
- Stacey Marden
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D, Astrazeneca, Boston, 35 Gatehouse Dr., Waltham, Massachusetts, 02451, USA.
| | - John M Campbell
- Analytical Development, GSK, 1250 South Collegeville Rd, Mail Stop UP1400, Upper Providence, Pennsylvania, 19426, USA.
| | - Neal Adams
- Scientific and Laboratory Services-Analytical Sciences, Pfizer Inc, Kalamazoo, Michigan, USA
| | - Ronan Coelho
- Regulatory Affairs, Eurofarma Laboratórios SA, Itapevi, São Paulo, Brazil
| | - Chris Foti
- Analytical Development and Operations, Gilead Sciences Inc., Foster City, California, USA
| | | | - Steven Hostyn
- Janssen Research & Development, LLC, a Johnson & Johnson Company, Predictive Analytics & Stability Sciences Coe, Beerse, Belgium
| | - Zongyun Huang
- Drug Product Development, Bristol-Myers Squibb Co., New Brunswick, New Jersey, USA
| | - Mariah Ultramari
- Spektra Soluções Científico-Regulatórias Ltda, São Paulo, Brazil
| | - Todd Zelesky
- Analytical Research & Development, Pfizer Inc., Groton, Connecticut, USA
| | | |
Collapse
|
2
|
Zelesky T, Baertschi SW, Foti C, Allain LR, Hostyn S, Franca JR, Li Y, Marden S, Mohan S, Ultramari M, Huang Z, Adams N, Campbell JM, Jansen PJ, Kotoni D, Laue C. Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective. J Pharm Sci 2023; 112:2948-2964. [PMID: 37690775 DOI: 10.1016/j.xphs.2023.09.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Revised: 09/01/2023] [Accepted: 09/01/2023] [Indexed: 09/12/2023]
Abstract
Forced degradation (i.e., stress testing) of small molecule drug substances and products is a critical part of the drug development process, providing insight into the intrinsic stability of a drug that is foundational to the development and validation of stability-indicating analytical methods. There is a lack of clarity in the scientific literature and regulatory guidance as to what constitutes an "appropriate" endpoint to a set of stress experiments. That is, there is no clear agreement regarding how to determine if a sample has been sufficiently stressed. Notably, it is unclear what represents a suitable justification for declaring a drug substance (DS) or drug product (DP) "stable" to a specific forced degradation condition. To address these concerns and to ensure all pharmaceutically-relevant, potential degradation pathways have been suitably evaluated, we introduce a two-endpoint classification designation supported by experimental data. These two endpoints are 1) a % total degradation target outcome (e.g., for "reactive" drugs) or, 2) a specified amount of stress, even in the absence of any degradation (e.g., for "stable" drugs). These recommended endpoints are based on a review of the scientific literature, regulatory guidance, and a forced degradation data set from ten global pharmaceutical companies. The experimental data set, derived from the Campbell et al. (2022) benchmarking study,1 provides justification for the recommendations. Herein we provide a single source reference for small molecule DS and DP forced degradation stress conditions and endpoint best practices to support regulatory submissions (e.g., marketing applications). Application of these forced degradation conditions and endpoints, as part of a well-designed, comprehensive and a sufficiently rigorous study plan that includes both the DS and DP, provides comprehensive coverage of pharmaceutically-relevant degradation and avoids unreasonably extreme stress conditions and drastic endpoint recommendations sometimes found in the literature.
Collapse
Affiliation(s)
- Todd Zelesky
- Analytical Research & Development, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA.
| | | | - Chris Foti
- Analytical Development and Operations, Gilead Sciences Inc., Foster City, California, USA.
| | | | - Steven Hostyn
- Predictive Analytics & Stability Sciences CoE, Janssen Pharmaceutica, Johnson & Johnson, Beerse, Belgium
| | | | - Yi Li
- Analytical Development and Operations, Gilead Sciences Inc., Foster City, California, USA
| | - Stacey Marden
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, MA, USA
| | - Shikhar Mohan
- Analytical Development and Operations, Gilead Sciences Inc., Foster City, California, USA
| | - Mariah Ultramari
- Spektra Soluções Científico-Regulatórias Ltda, São Paulo, Brazil
| | - Zongyun Huang
- Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, NJ 08901, USA
| | - Neal Adams
- Pfizer, Scientific and Laboratory Services - Analytical Sciences, Pfizer Inc., 7000 Portage Road, Kalamazoo, MI 49001, USA
| | - John M Campbell
- Analytical Development, GSK, Upper Providence, PA 19426, USA
| | - Patrick J Jansen
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
| | - Dorina Kotoni
- Chemical & Analytical Development, Novartis Pharma AG, Basel, Switzerland
| | - Christian Laue
- Chemical & Pharmaceutical Development, Merck Healthcare KGaA, Darmstadt, Germany
| |
Collapse
|
3
|
Iyer J, Brunsteiner M, Ray A, Davis A, Saraf I, Paudel A. Theoretical and Experimental Investigation of Autoxidation Propensity of Selected Drugs in Solution State. Mol Pharm 2023; 20:1768-1778. [PMID: 36757102 DOI: 10.1021/acs.molpharmaceut.2c00967] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
The C-H bond dissociation energy (BDE) of drug molecules is often used to estimate their relative propensities to undergo autoxidation. BDE calculations based on electronic structures provide a convenient means to estimate the risk for a given compound to degrade via autoxidation. This study aimed to verify the utility of calculated C-H BDEs of a range of drug molecules in predicting their autoxidation propensities, in the solution state. For the autoxidation study, 2,2'-azobis (2-methylpropionitrile) was employed as the solution state stressor, and the experimental reaction rate constants were determined employing ultraperformance liquid chromatographic (UPLC) methods. Reaction rates in the solution state were compared to the calculated C-H BDE values of the respective compounds. The results indicated a poor correlation for compounds in the solution state, and their relative stabilities could not be explained with C-H BDE. On the other hand, a favorable relationship was observed between the relative extent of ionization and the autoxidation rates of the selected compounds. In the solution state, factors such as the type and extent of drug ionization, degree and type of solvation have been shown to contribute to differences in reactivity. By applying the computational method involving the effect of H-atom abstraction and potential ionization sites in the molecule, the calculated C-H BDE should relate better to the experimental autoxidation rates.
Collapse
Affiliation(s)
- Jayant Iyer
- Research Center Pharmaceutical Engineering GmbH (RCPE), Graz 8010, Austria
| | | | - Andrew Ray
- Dew Modalities Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Adrian Davis
- Pfizer Worldwide Research and Development, Sandwich, Kent CT13 9NJ, United Kingdom
| | - Isha Saraf
- Research Center Pharmaceutical Engineering GmbH (RCPE), Graz 8010, Austria
| | - Amrit Paudel
- Research Center Pharmaceutical Engineering GmbH (RCPE), Graz 8010, Austria.,Graz University of Technology, Institute of Process and Particle Engineering, Graz 8010, Austria
| |
Collapse
|
4
|
Wu H, Grinberg Dana A, Ranasinghe DS, Pickard FC, Wood GPF, Zelesky T, Sluggett GW, Mustakis J, Green WH. Kinetic Modeling of API Oxidation: (2) Imipramine Stress Testing. Mol Pharm 2022; 19:1526-1539. [DOI: 10.1021/acs.molpharmaceut.2c00043] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Haoyang Wu
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Alon Grinberg Dana
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Wolfson Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Duminda S. Ranasinghe
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Frank C. Pickard
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Geoffrey P. F. Wood
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Todd Zelesky
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Gregory W. Sluggett
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jason Mustakis
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - William H. Green
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
5
|
Grinberg Dana A, Wu H, Ranasinghe DS, Pickard FC, Wood GPF, Zelesky T, Sluggett GW, Mustakis J, Green WH. Kinetic Modeling of API Oxidation: (1) The AIBN/H 2O/CH 3OH Radical "Soup". Mol Pharm 2021; 18:3037-3049. [PMID: 34236207 DOI: 10.1021/acs.molpharmaceut.1c00261] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Stress testing of active pharmaceutical ingredients (API) is an important tool used to gauge chemical stability and identify potential degradation products. While different flavors of API stress testing systems have been used in experimental investigations for decades, the detailed kinetics of such systems as well as the chemical composition of prominent reactive species, specifically reactive oxygen species, are unknown. As a first step toward understanding and modeling API oxidation in stress testing, we investigated a typical radical "soup" solution an API is subject to during stress testing. Here we applied ab initio electronic structure calculations to automatically generate and refine a detailed chemical kinetics model, taking a fresh look at API oxidation. We generated a detailed kinetic model for a representative azobis(isobutyronitrile) (AIBN)/H2O/CH3OH stress-testing system with a varied cosolvent ratio (50%/50%-99.5%/0.5% vol water/methanol) for 5.0 mM AIBN and representative pH values of 4-10 at 40 °C that was stirred and open to the atmosphere. At acidic conditions, hydroxymethyl alkoxyl is the dominant alkoxyl radical, and at basic conditions, for most studied initial methanol concentrations, cyanoisopropyl alkoxyl becomes the dominant alkoxyl radical, albeit at an overall lower concentration. At acidic conditions, the levels of cyanoisopropyl peroxyl, hydroxymethyl peroxyl, and hydroperoxyl radicals are relatively high and comparable, while, at both neutral and basic pH conditions, superoxide becomes the prominent radical in the system. The present work reveals the prominent species in a common model API stress testing system at various cosolvent and pH conditions, sets the stage for an in-depth quantitative API kinetic study, and demonstrates the usage of novel software tools for automated chemical kinetic model generation and ab initio refinement.
Collapse
Affiliation(s)
- Alon Grinberg Dana
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.,Wolfson Department of Chemical Engineering, Technion, Israel Institute of Technology, Haifa 3200003, Israel
| | - Haoyang Wu
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Duminda S Ranasinghe
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Frank C Pickard
- Pfizer Global Research & Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Geoffrey P F Wood
- Pfizer Global Research & Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Todd Zelesky
- Pfizer Global Research & Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Gregory W Sluggett
- Pfizer Global Research & Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jason Mustakis
- Pfizer Global Research & Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - William H Green
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
6
|
Lin J, Huang T, Feng M, Li D, Zhao D, Wang J, Jin J, Zhu W, Li M. Solution degradant of mirabegron extended release tablets resulting from a Strecker-like reaction between mirabegron, minute amounts of hydrogen cyanide in acetonitrile, and formaldehyde in PEG during sample preparation. J Pharm Biomed Anal 2019; 168:181-188. [DOI: 10.1016/j.jpba.2019.01.045] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2018] [Revised: 01/22/2019] [Accepted: 01/26/2019] [Indexed: 10/27/2022]
|